Cargando…

Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice

The first oral form of the glucagon-like peptide-1 receptor agonist, oral semaglutide, has recently been launched and potently controls glycemia and body weight in subjects with type 2 diabetes. This drug carries the absorption enhancer and requires specific protocols of administration. The mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakhat, Yermek, Wang, Lei, Han, Wanxin, Rustemova, Aktolkyn, Kulzhanova, Nazymgul, Yamada, Yuichiro, Yabe, Daisuke, Seino, Yutaka, Yada, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489807/ https://www.ncbi.nlm.nih.gov/pubmed/37686797 http://dx.doi.org/10.3390/nu15173765

Ejemplares similares

d-Allulose Inhibits Ghrelin-Responsive, Glucose-Sensitive and Neuropeptide Y Neurons in the Arcuate Nucleus and Central Injection Suppresses Appetite-Associated Food Intake in Mice
por: Rakhat, Yermek, et al.
Publicado: (2022)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
por: Yamada, Yuichiro, et al.
Publicado: (2021)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
por: Yabe, Daisuke, et al.
Publicado: (2022)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

How Important Is Eating Rate in the Physiological Response to Food Intake, Control of Body Weight, and Glycemia?
por: Argyrakopoulou, Georgia, et al.
Publicado: (2020)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

The journey to understanding incretin systems: Theory, practice and more theory
por: Yabe, Daisuke, et al.
Publicado: (2019)

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
por: Usui, Ryota, et al.
Publicado: (2019)

The Asian Association for the Study of Diabetes: The first 10 years and the next 10 years
por: Seino, Yutaka, et al.
Publicado: (2020)

Efficacy and Safety of 6-Month High Dietary Protein Intake in Hospitalized Adults Aged 75 or Older at Nutritional Risk: An Exploratory, Randomized, Controlled Study
por: Moyama, Shota, et al.
Publicado: (2023)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Fasting inhibits excitatory synaptic input on paraventricular oxytocin neurons via neuropeptide Y and Y1 receptor, inducing rebound hyperphagia, and weight gain
por: Wang, Lei, et al.
Publicado: (2022)

Effects of Non-Nutritive Sweeteners on Energy Intake, Body Weight and Postprandial Glycemia in Healthy and with Altered Glycemic Response Rats
por: Ramos-García, Meztli, et al.
Publicado: (2021)

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
por: Blundell, John, et al.
Publicado: (2017)

Wegovy (semaglutide): a new weight loss drug for chronic weight management
por: Singh, Gurdeep, et al.
Publicado: (2022)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes
por: Gibbons, Catherine, et al.
Publicado: (2020)

Dietary Intake in Early Pregnancy and Glycemia in Late Pregnancy among Women with Obesity
por: Garnæs, Kirsti Krohn, et al.
Publicado: (2021)

Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
por: Aranäs, Cajsa, et al.
Publicado: (2023)

Ninjin'yoeito Targets Distinct Ca(2+) Channels to Activate Ghrelin-Responsive vs. Unresponsive NPY Neurons in the Arcuate Nucleus
por: Goswami, Chayon, et al.
Publicado: (2020)

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
por: Ghusn, Wissam, et al.
Publicado: (2022)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice
por: Ahrén, Bo, et al.
Publicado: (2021)

Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake
por: Cawthon, Carolina R, et al.
Publicado: (2023)

Antismoking agents do not contribute synergistically to semaglutide’s ability to reduce alcohol intake in rats
por: Aranäs, Cajsa, et al.
Publicado: (2023)

Genetic variation of fasting glucose and changes in glycemia in response to 2-year weight-loss diet intervention: the POUNDS Lost trial
por: Wang, Tiange, et al.
Publicado: (2016)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood
por: Kahkoska, Anna R, et al.
Publicado: (2020)

Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open‐label, 3‐arm parallel comparative, exploratory study
por: Yabe, Daisuke, et al.
Publicado: (2017)

Association of Food Insecurity with Changes in Diet Quality, Weight, and Glycemia Over Two Years in Adults with Prediabetes and Type 2 Diabetes on Medicaid
por: Gu, Kristine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ufhhf38v5braot52jju960pi4i